Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03793010 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis
A Phase 3 study, sponsored by Pacira Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 70
- Enrollment target
NCT03793010 is a Phase 3 study that was terminated before completion, run by Pacira Pharmaceuticals. The registered enrollment target is 70 participants.
The verdict
NCT03793010, a Phase 3 study, was terminated before completion, sponsored by Pacira Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a two-part, multi-center, randomized, double-blind, placebo-controlled, parallel-group study in patients with hip OA. Approximately 70 patients will be enrolled in Part I and approximately 440 patients will be enrolled in Part II of the study. In each part, patients will be randomized to one of two treatment groups (1:1) and treated with a single IA injection of either 32 mg FX006 or normal saline.
Interventions
- DRUG Normal saline
- DRUG FX006
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2018-12-12 |
| Est. Completion | 2019-08-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03793010
The ClinicalTrials.gov registry entry for NCT03793010 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT03793010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03793010 about?
NCT03793010 is a clinical study titled "Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis". This is a two-part, multi-center, randomized, double-blind, placebo-controlled, parallel-group study in patients with hip OA. Approximately 70 patients will be enrolled in Part I and approximately 440 patients will be enrolled in Part II of the study. In each part, patients will be randomized to one...
What is the current status of trial NCT03793010?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 70 participants. The study started on 2018-12-12. Estimated completion is 2019-08-07.
What interventions are being tested in trial NCT03793010?
The interventions under investigation include: Normal saline (DRUG), FX006 (DRUG).
Who is sponsoring clinical trial NCT03793010?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.